dwinnex.com

Cytori Therapeutics, Inc. [NASDAQ: CYTX] opened at $0.23 and closed at $0.22 a share within trading session on 13/06/2019. That means that the stock gained by 11.22% compared to the closing price from a day before, when the stock touched $0.25.

Between the start and the closing of the latest trading session, Cytori Therapeutics, Inc. [NASDAQ: CYTX] had 2.9 million shares being bought and sold. In the last three months, average trading volumes hovered around 625.25K shares. During the last week, volatility in the share price was set at 18.07%, which placed the metric for the last 30 days at 12.09%. The price of the stock additionally went down to $0.21 during that period and CYTX managed to take a rebound to $2.39 in the last 52 weeks.

Cytori Therapeutics, Inc. [NASDAQ:CYTX]: Analyst Rating and Earnings

Stock market traders oftentimes pay a lot of attention to what top analysts say regarding a potential investment. Its stock price has been found in the range of 0.21 to 2.39. This is compared to its latest closing price of $0.22.

Pay attention for this company’s financial results, of which the next release is scheduled to happen on Tue 13 Aug (In 60 Days).

Fundamental Analysis of Cytori Therapeutics, Inc. [CYTX]

Now let’s turn to look at profitability: with a current Operating Margin for Cytori Therapeutics, Inc. [CYTX] sitting at -410.81 and its Gross Margin at +35.36.

This company’s Return on Total Capital is -65.50, and its Return on Invested Capital has reached -65.50%. Its Return on Equity is -165.94, and its Return on Assets is -54.39. These metrics suggest that this Cytori Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Cytori Therapeutics, Inc. [CYTX] has generated a Total Debt to Total Equity ratio of 271.81. Similarly, its Total Debt to Total Capital is 73.10, while its Total Debt to Total Assets stands at 59.20.

What about valuation? This company’s Enterprise Value to EBITDA is -1.07. The Enterprise Value to Sales for this firm is now 3.85, and its Total Debt to Enterprise Value stands at 1.24. Cytori Therapeutics, Inc. [CYTX] has a Price to Book Ratio of 0.82.

Shifting the focus to workforce efficiency, Cytori Therapeutics, Inc. [CYTX] earns $99,216 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 11.58 and its Total Asset Turnover is 0.13. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.38 and its Current Ratio is 0.55. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.

Cytori Therapeutics, Inc. [CYTX] has 23.71M shares outstanding, amounting to a total market cap of $5.88M. Its stock price has been found in the range of 0.21 to 2.39. At its current price, it has moved down by -89.63% from its 52-week high, and it has moved up 18.05% from its 52-week low.

This stock’s Beta value is currently 2.03, which indicates that it is 18.07% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 46.12. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Cytori Therapeutics, Inc. [CYTX] a Reliable Buy?

Cytori Therapeutics, Inc. [CYTX] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.